Podcast Medicom Medical Publishers

EULAR 2020 E-Congress - Highlights

June 05, 2020
Podcast Medicom Medical Publishers
EULAR 2020 E-Congress - Highlights
Chapters
0:16
COVID-19 and inflammatory rheumatic disease: some key issues answered
2:06
Upadacitinib provides fast onset of improvement in psoriatic arthritis
4:12
Lower venous thromboembolism risk with TNF inhibitors in rheumatoid arthritis
6:40
New nanoparticle promising future agent in rheumatoid arthritis
9:22
Rozibafusp alfa effective and tolerable in rheumatoid arthritis
11:45
Olokizumab significantly improves rheumatoid arthritis features
Podcast Medicom Medical Publishers
EULAR 2020 E-Congress - Highlights
Jun 05, 2020

Summary of 6 articles presented at the European E-Congress of Rheumatology:

  1. COVID-19 and inflammatory rheumatic disease: some key issues answered
  2. Upadacitinib provides fast onset of improvement in psoriatic arthritis
  3. Lower venous thromboembolism risk with TNF inhibitors in rheumatoid arthritis
  4. New nanoparticle promising future agent in rheumatoid arthritis
  5. Rozibafusp alfa effective and tolerable in rheumatoid arthritis
  6. Olokizumab significantly improves rheumatoid arthritis features
Show Notes Chapter Markers

Summary of 6 articles presented at the European E-Congress of Rheumatology:

  1. COVID-19 and inflammatory rheumatic disease: some key issues answered
  2. Upadacitinib provides fast onset of improvement in psoriatic arthritis
  3. Lower venous thromboembolism risk with TNF inhibitors in rheumatoid arthritis
  4. New nanoparticle promising future agent in rheumatoid arthritis
  5. Rozibafusp alfa effective and tolerable in rheumatoid arthritis
  6. Olokizumab significantly improves rheumatoid arthritis features
COVID-19 and inflammatory rheumatic disease: some key issues answered
Upadacitinib provides fast onset of improvement in psoriatic arthritis
Lower venous thromboembolism risk with TNF inhibitors in rheumatoid arthritis
New nanoparticle promising future agent in rheumatoid arthritis
Rozibafusp alfa effective and tolerable in rheumatoid arthritis
Olokizumab significantly improves rheumatoid arthritis features